Business · 07/12/2022Updated: 10/17/2026 · 1 min read
FDA Approves Product Redeeming Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved IMJUDO (tremelimumab), a product that meets the criteria for redeeming a priority review voucher, following the issuance of a notice as required by the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →